- 3TC (lamivudine, Epivir)
- Abacavir (Ziagen)
- Atazanavir (Reyataz)
- Atripla
- AZT (zidovudine, Retrovir)
- Combivir
- d4T (stavudine, Zerit)
- Darunavir (Prezista)
- ddI (didanosine, Videx / VidexEC)
- Efavirenz (Sustiva)
- Fosamprenavir (Telzir)
- FTC (emtricitabine, Emtriva)
- Indinavir (Crixivan)
- Kaletra
- Kivexa
- Lopinavir
- Nelfinavir (Viracept)
- Nevirapine (Viramune)
- Ritonavir (Norvir)
- Saquinavir (Invirase)
- T-20 (enfuvirtide, Fuzeon)
- Tenofovir disoproxil (Viread)
- Tipranavir (Aptivus)
- Trizivir
- Truvada
Kaletra
Kaletra is a fixed-dose combination containing the anti-HIV drugs lopinavir and ritonavir. Lopinavir is only available in Kaletra capsules, tablets and oral solution. However, ritonavir, which is used to boost lopinavir levels in the blood, is also marketed separately as Norvir.
Protease inhibitors block the activity of the HIV protease (or proteinase) enzyme to slow HIV replication and delay damage to the immune system. For more information on how protease inhibitors work, see Protease inhibitors.
Kaletra is made by Abbott Laboratories. It was approved for marketing in the United States in September 2000 and in the European Union in April 2001.
latest aidsmap news
- 'Hidden epidemic' of HIV amongst African migrants in the United States
- Blood viral load predicts HIV transmission better than semen viral load in small study among MSM
- Infectiousness and antiretroviral therapy: reports look set to further fuel the debate
- Albendazole treatment of helminth co-infection in Kenyan HIV patients raises CD4 counts
- Justice Edwin Cameron calls for a campaign against 'misguided criminal laws and prosecutions'
- HIV prevalence and incidence in Uganda on the way up
- Half of Russian XDR-TB patients cured with aggressive treatment
- Updated British HIV pregnancy guidelines published
- Incidence increasing of HIV-associated multicentric Castleman's disease, a relatively rare lymphatic cancer
- Rapid progression of liver fibrosis in HIV-positive gay men recently infected with hepatitis C
